1. Levocabastine Eye Drops do not Affect Accommodative Capacity in Volunteers and Intraocular Pressure in Glaucoma Patients
- Author
-
Wohlrab Tm, Sebastian Wolf, and Andreas Remky
- Subjects
Male ,Intraocular pressure ,medicine.medical_specialty ,Visual acuity ,genetic structures ,medicine.medical_treatment ,Eye disease ,Glaucoma ,medicine.disease_cause ,03 medical and health sciences ,0302 clinical medicine ,Piperidines ,Reference Values ,Ophthalmology ,medicine ,Humans ,Intraocular Pressure ,Aged ,Aged, 80 and over ,business.industry ,Accommodation, Ocular ,Eye drop ,General Medicine ,Middle Aged ,medicine.disease ,eye diseases ,Levocabastine ,Allergic conjunctivitis ,Histamine H1 Antagonists ,030221 ophthalmology & optometry ,Female ,sense organs ,Ophthalmic Solutions ,Irritation ,medicine.symptom ,business ,030217 neurology & neurosurgery ,medicine.drug - Abstract
Levocabastine is a potent and highly selective H 1 -receptor antagonist specifically developed for the topical treatment of allergic conjunctivitis. This study assessed the effects of levocabastine eye drops on accommodative capacity in 20 healthy volunteers and on parameters influencing glaucoma in 12 glaucoma patients. A single dose of levocabastine (0.5 mg/ml) did not influence accommodative capacity, pupil diameter, or intraocular pressure (IOP) in volunteers. Similarly, levocabastine (0.5 mg/ml, one drop in each eye twice daily) for two weeks was well tolerated by patients with glaucoma. Measurement of IOP, iridocorneal angle, depth of the anterior chamber, visual acuity and near-point in these patients provided no evidence of exacerbation of glaucoma or interactions with concurrent antiglaucoma medication. Application site reactions (local irritation and ocular pain) were the only adverse effects, with an incidence comparable to placebo-treated controls. In conclusion, ocular levocabastine appears to be well tolerated, with no apparent effects on accommodative capacity or glaucoma.
- Published
- 1995